Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.21 USD | +3.99% | +10.73% | +26.46% |
05-13 | Oppenheimer Adjusts Achieve Life Sciences Price Target to $11 From $18, Maintains Outperform Rating | MT |
05-09 | Transcript : Achieve Life Sciences, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.46% | 172M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- ACHV Stock
- News Achieve Life Sciences, Inc.
- Achieve Life Sciences Reports 'Positive' Topline Results From Phase 2 Trial of Cytisinicline for Vaping Cessation